BioNexus Gene Lab's revenue per share for the
three
months ended in Mar. 2024 was $0.14.
BioNexus Gene Lab's revenue per share for the trailing twelve months (TTM) ended in Mar. 2024 was $0.59.
Warning Sign:
BioNexus Gene Lab Corp revenue per share has been in decline over the past 3 years.
During the past 12 months, the average Revenue Per Share Growth Rate of BioNexus Gene Lab was -16.60% per year.
During the past 3 years, the average Revenue Per Share Growth Rate was -22.60% per year.
During the past 5 years, the average Revenue Per Share Growth Rate was 119.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for BioNexus Gene Lab's Revenue per Share or its related term are showing as below:
BGLC'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -22.6 Med: 234.7 Max: 269.7
Current: -22.6
During the past 6 years, BioNexus Gene Lab's highest 3-Year average Revenue Per Share Growth Rate was 269.70% per year. The lowest was -22.60% per year. And the median was 234.70% per year.
BGLC's 3-Year Revenue Growth Rate is ranked worse than 96.34% of 1475
companies
in the Chemicals industry
Industry Median: 8.4
vs BGLC: -22.60
BioNexus Gene Lab Revenue per Share Historical Data
The historical data trend for BioNexus Gene Lab's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of BioNexus Gene Lab's Revenue per Share
For the Specialty Chemicals subindustry, BioNexus Gene Lab's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioNexus Gene Lab's PS Ratio Distribution in the Chemicals Industry
For the Chemicals industry and Basic Materials sector, BioNexus Gene Lab's PS Ratio distribution charts can be found below:
* The bar in red indicates where BioNexus Gene Lab's PS Ratio falls into.
BioNexus Gene Lab Revenue per Share Calculation
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
BioNexus Gene Lab's Revenue Per Share for the fiscal year that ended in Dec. 2023 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.59
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioNexus Gene Lab (NAS:BGLC) Revenue per Share Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
BioNexus Gene Lab Revenue per Share Related Terms
Thank you for viewing the detailed overview of BioNexus Gene Lab's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
BioNexus Gene Lab (BioNexus Gene Lab) Business Description
BioNexus Gene Lab Corp is an emerging molecular diagnostics company focused on the application of functional genomics to enable early diagnosis and personalized health management. It focuses on developing and marketing safe, effective, and non-invasive blood tests for the early detection of diseases. The company's non-invasive blood tests analyze changes in ribonucleic acid (or RNA) to detect the potentiality of 11 different diseases. These diseases include eight cancers (nasopharyngeal, lung, liver, stomach, breast, cervical, prostate, and colon), two bowel diseases (colitis and Crohn), and osteoarthritis.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BGLC has been successfully added to your 